Astrana Health Inc (ASTH)vsNovartis AG ADR (NVS)
ASTH
Astrana Health Inc
$34.14
-2.50%
HEALTHCARE · Cap: $1.95B
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 1678% more annual revenue ($56.58B vs $3.18B). NVS leads profitability with a 23.9% profit margin vs 0.7%. NVS trades at a lower P/E of 21.2x. NVS earns a higher WallStSmart Score of 51/100 (C-).
ASTH
Hold44
out of 100
Grade: D
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ASTH.
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 42.9% year-over-year
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
ROE of 4.5% — below average capital efficiency
0.7% margin — thin
Operating margin of 1.9%
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : ASTH
The strongest argument for ASTH centers on Revenue Growth, Price/Book. Revenue growth of 42.9% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : ASTH
The primary concerns for ASTH are Market Cap, Return on Equity, Profit Margin. A P/E of 76.1x leaves little room for execution misses. Thin 0.7% margins leave little buffer for downturns.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Key Dynamics to Monitor
ASTH profiles as a hypergrowth stock while NVS is a declining play — different risk/reward profiles.
ASTH carries more volatility with a beta of 0.77 — expect wider price swings.
ASTH is growing revenue faster at 42.9% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 44/100), backed by strong 23.9% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Astrana Health Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Astrana Health, Inc., Inc., a physician-centric technology-powered healthcare management company, provides medical care services in the United States. The company is headquartered in Alhambra, California.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?